Other Species / Isoforms
  CCDC9 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S60-p
TAPRKGRsVEKENVA
0 5
CCDC9 (human) TAPRKGRsVEKENVA S60-p
CCDC9 (mouse) TAPRKSRsMEKENMA S60-p
CCDC9 (rat) TAPRKSRSMEKENMA S60
S80-p
NLGPSRRsPGtPRPP
Upstream
0 33
Treatment
  • dasatinib
  • nocodazole
CCDC9 (human) NLGPSRRsPGtPRPP S80-p
CCDC9 (mouse) SLGPSRRtPGTPRPP T79-p
CCDC9 (rat) NLGPSRRTPGTPRPP T79
T83-p
PSRRsPGtPRPPGAS
0 17
CCDC9 (human) PSRRsPGtPRPPGAS T83-p
CCDC9 (mouse) PSRRtPGTPRPPGAS T82
CCDC9 (rat) PSRRTPGTPRPPGAS T82
R94-m1
PGASKGGrtPPQQGG
0 16
CCDC9 (human) PGASKGGrtPPQQGG R94-m1
CCDC9 (mouse) PGASRGGRTHPQQGG R93
CCDC9 (rat) PGASRGGRTHPQQGG R93
T95-p
GASKGGrtPPQQGGr
Upstream
0 4
Treatment
  • nocodazole
CCDC9 (human) GASKGGrtPPQQGGr T95-p
CCDC9 (mouse) GASRGGRTHPQQGGR T94
CCDC9 (rat) GASRGGRTHPQQGGR T94
R102-m1
tPPQQGGrAGMGrAs
0 20
CCDC9 (human) tPPQQGGrAGMGrAs R102-m1
CCDC9 (mouse) THPQQGGRAGVGrAS R101
CCDC9 (rat) THPQQGGRAGVGRAS R101
R107-m1
GGrAGMGrAsrsWEG
0 25
CCDC9 (human) GGrAGMGrAsrsWEG R107-m1
CCDC9 (mouse) GGRAGVGrASQGWED R106-m1
CCDC9 (rat) GGRAGVGRASRGWED R106
S109-p
rAGMGrAsrsWEGsP
0 1
CCDC9 (human) rAGMGrAsrsWEGsP S109-p
CCDC9 (mouse) RAGVGrASQGWEDGA S108
CCDC9 (rat) RAGVGRASRGWEDGA S108
R110-m1
AGMGrAsrsWEGsPG
0 4
CCDC9 (human) AGMGrAsrsWEGsPG R110-m1
CCDC9 (mouse) AGVGrASQGWEDGAG Q109
CCDC9 (rat) AGVGRASRGWEDGAG R109
S111-p
GMGrAsrsWEGsPGE
0 2
CCDC9 (human) GMGrAsrsWEGsPGE S111-p
CCDC9 (mouse) GVGrASQGWEDGAGE G110
CCDC9 (rat) GVGRASRGWEDGAGE G110
S115-p
AsrsWEGsPGEQPrG
0 2
CCDC9 (human) AsrsWEGsPGEQPrG S115-p
CCDC9 (mouse) ASQGWEDGAGEQLrG G114
CCDC9 (rat) ASRGWEDGAGEQLRG G114
R121-m1
GsPGEQPrGGGAGGr
Upstream
0 47
Treatment
  • actinomycin_D
CCDC9 (human) GsPGEQPrGGGAGGr R121-m1
CCDC9 (mouse) DGAGEQLrGGPGGrG R120-m1
CCDC9 (rat) DGAGEQLRGGTGGRG R120
R128-m1
rGGGAGGrGrrGrGr
Upstream
0 46
Treatment
  • actinomycin_D
CCDC9 (human) rGGGAGGrGrrGrGr R128-m1
CCDC9 (mouse) LrGGPGGrGrRGRGR R126-m1
CCDC9 (rat) LRGGTGGRGRRGRGR R126
R130-m1
GGAGGrGrrGrGrGs
Upstream
0 46
Treatment
  • actinomycin_D
CCDC9 (human) GGAGGrGrrGrGrGs R130-m1
CCDC9 (mouse) GGPGGrGrRGRGRGS R128-m1
CCDC9 (rat) GGTGGRGRRGRGRGS R128
R131-m2
GAGGrGrrGrGrGsP
0 5
CCDC9 (human) GAGGrGrrGrGrGsP R131-m2
CCDC9 (mouse) GPGGrGrRGRGRGSP R129
CCDC9 (rat) GTGGRGRRGRGRGSP R129
R133-m2
GGrGrrGrGrGsPHL
0 5
CCDC9 (human) GGrGrrGrGrGsPHL R133-m2
CCDC9 (mouse) GGrGrRGRGRGSPHL R131
CCDC9 (rat) GGRGRRGRGRGSPHL R131
R135-m1
rGrrGrGrGsPHLSG
0 4
CCDC9 (human) rGrrGrGrGsPHLSG R135-m1
CCDC9 (mouse) rGrRGRGRGSPHLLG R133
CCDC9 (rat) RGRRGRGRGSPHLLG R133
R135-m2
rGrrGrGrGsPHLSG
0 5
CCDC9 (human) rGrrGrGrGsPHLSG R135-m2
CCDC9 (mouse) rGrRGRGRGSPHLLG R133
CCDC9 (rat) RGRRGRGRGSPHLLG R133
S137-p
rrGrGrGsPHLSGAG
0 9
CCDC9 (human) rrGrGrGsPHLSGAG S137-p
CCDC9 (mouse) rRGRGRGSPHLLGAG S135
CCDC9 (rat) RRGRGRGSPHLLGAG S135
K166-ub
RRRQNIEkMNEEMEK
0 1
CCDC9 (human) RRRQNIEkMNEEMEK K166-ub
CCDC9 (mouse) RRRQNIEKMNEEMEK K164
CCDC9 (rat) RRRQNIEKMNEEMER K164
Y177-p
EMEKIAEyERNQREG
0 8
CCDC9 (human) EMEKIAEyERNQREG Y177-p
CCDC9 (mouse) EMEKIAEYERNQREG Y175
CCDC9 (rat) EMERIAEYERNQREG Y175
S202-p
LDDPRRRsGPLEESE
Upstream
0 18
Treatment
  • ischemia
  • nocodazole
CCDC9 (human) LDDPRRRsGPLEESE S202-p
CCDC9 (mouse) LDDPRRRGGPLEESE G200
CCDC9 (rat) LDDPRRRGGPLEESE G200
R221-m1
EESRRHGrNWGGPDF
0 2
CCDC9 (human) EESRRHGrNWGGPDF R221-m1
CCDC9 (mouse) EGSRRHGRNWGGSDF R219
CCDC9 (rat) EGSRRHGrNWGGSDF R219-m1
R243-m1
EHERQGRrAGLGsAG
0 2
CCDC9 (human) EHERQGRrAGLGsAG R243-m1
CCDC9 (mouse) EQERQGRRAGLGSGG R241
CCDC9 (rat) QERQQGRRAGLGSGG R242
S248-p
GRrAGLGsAGDMTLs
0 4
CCDC9 (human) GRrAGLGsAGDMTLs S248-p
CCDC9 (mouse) GRRAGLGSGGDMTMS S246
CCDC9 (rat) GRRAGLGSGGDMTMS S247
S255-p
sAGDMTLsMTGRERs
0 1
CCDC9 (human) sAGDMTLsMTGRERs S255-p
CCDC9 (mouse) SGGDMTMSMTGRERS S253
CCDC9 (rat) SGGDMTMSMTGRERS S254
S262-p
sMTGRERsEyLRWKQ
0 1
CCDC9 (human) sMTGRERsEyLRWKQ S262-p
CCDC9 (mouse) SMTGRERSEYLRWKQ S260
CCDC9 (rat) SMTGRERSEYLRWKQ S261
Y264-p
TGRERsEyLRWKQER
0 2
CCDC9 (human) TGRERsEyLRWKQER Y264-p
CCDC9 (mouse) TGRERSEYLRWKQER Y262
CCDC9 (rat) TGRERSEYLRWKQER Y263
T286-p
LQRHRKPtGQWRREW
0 14
CCDC9 (human) LQRHRKPtGQWRREW T286-p
CCDC9 (mouse) LQRHRKPTGQWRREW T284
CCDC9 (rat) LQRHRKPTGQWRREW T285
D299-ca
EWDAEKTdGMFKDGP
0 1
CCDC9 (human) EWDAEKTdGMFKDGP D299-ca
CCDC9 (mouse) EWDAEKTDGMFKDGP D297
CCDC9 (rat) EWDAEKTDGMFKDGP D298
Y316-p
AHEPSHRyDDQAWAR
0 2
CCDC9 (human) AHEPSHRyDDQAWAR Y316-p
CCDC9 (mouse) THELSHRYDDQAWAR Y314
CCDC9 (rat) THEPSHRYDDQAWAR Y315
S335-p
PTFGEFLsQHKAEAS
0 2
CCDC9 (human) PTFGEFLsQHKAEAS S335-p
CCDC9 (mouse) PTFGEFLSQHKAEVS S333
CCDC9 (rat) PTFGEFLSQHKAEVN S334
K348-ac
ASSRRRRkssRPQAk
0 1
CCDC9 (human) ASSRRRRkssRPQAk K348-ac
CCDC9 (mouse) VSSRRRRKNSRPQAK K346
CCDC9 (rat) VNSRRRRKNSRPQAK K347
S349-p
SSRRRRkssRPQAkA
0 5
CCDC9 (human) SSRRRRkssRPQAkA S349-p
CCDC9 (mouse) SSRRRRKNSRPQAKV N347
CCDC9 (rat) NSRRRRKNSRPQAKV N348
S350-p
SRRRRkssRPQAkAA
0 2
CCDC9 (human) SRRRRkssRPQAkAA S350-p
CCDC9 (mouse) SRRRRKNSRPQAKVA S348
CCDC9 (rat) SRRRRKNSRPQAKVA S349
K355-ac
kssRPQAkAAPRAys
0 1
CCDC9 (human) kssRPQAkAAPRAys K355-ac
CCDC9 (mouse) KNSRPQAKVAPRAYs K353
CCDC9 (rat) KNSRPQAKVAPRAYS K354
Y361-p
AkAAPRAysDHDDRW
0 1
CCDC9 (human) AkAAPRAysDHDDRW Y361-p
CCDC9 (mouse) AKVAPRAYsDHDNRW Y359
CCDC9 (rat) AKVAPRAYSDHDNRW Y360
S362-p
kAAPRAysDHDDRWE
0 10
CCDC9 (human) kAAPRAysDHDDRWE S362-p
CCDC9 (mouse) KVAPRAYsDHDNRWE S360-p
CCDC9 (rat) KVAPRAYSDHDNRWE S361
S376-p
ETKEGAAsPAPEtPQ
Upstream
0 18
Treatment
  • ischemia
  • selumetinib
  • vemurafenib
CCDC9 (human) ETKEGAAsPAPEtPQ S376-p
CCDC9 (mouse) ETREEAVSSAPESSQ S374
CCDC9 (rat) ETKEEAVSPAPKSSQ S375
T381-p
AAsPAPEtPQPtsPE
Upstream
0 39
Treatment
  • selumetinib
  • vemurafenib
CCDC9 (human) AAsPAPEtPQPtsPE T381-p
CCDC9 (mouse) AVSSAPESSQSISLE S379
CCDC9 (rat) AVSPAPKSSQSMSLE S380
T385-p
APEtPQPtsPEtsPK
0 22
CCDC9 (human) APEtPQPtsPEtsPK T385-p
CCDC9 (mouse) APESSQSISLEETPT I383
CCDC9 (rat) APKSSQSMSLEETPT M384
S386-p
PEtPQPtsPEtsPKE
Upstream
0 18
Treatment
  • selumetinib
CCDC9 (human) PEtPQPtsPEtsPKE S386-p
CCDC9 (mouse) PESSQSISLEETPTQ S384
CCDC9 (rat) PKSSQSMSLEETPTQ S385
T389-p
PQPtsPEtsPKETPM
0 19
CCDC9 (human) PQPtsPEtsPKETPM T389-p
CCDC9 (mouse) gap -
CCDC9 (rat) gap -
S390-p
QPtsPEtsPKETPMQ
0 7
CCDC9 (human) QPtsPEtsPKETPMQ S390-p
CCDC9 (mouse) gap -
CCDC9 (rat) gap -
T485-p
LEPQAPGtPSsPFSP
0 1
CCDC9 (human) LEPQAPGtPSsPFSP T485-p
CCDC9 (mouse) LLSPVPVEPPIPFSP E497
CCDC9 (rat) LLSPVPVEPPSPFSP E500
S488-p
QAPGtPSsPFSPPSG
0 1
CCDC9 (human) QAPGtPSsPFSPPSG S488-p
CCDC9 (mouse) PVPVEPPIPFSPSED I500
CCDC9 (rat) PVPVEPPSPFSPSED S503
S521-p
THLAGALsPGEAWPF
Upstream
0 12
Treatment
  • ischemia
CCDC9 (human) THLAGALsPGEAWPF S521-p
CCDC9 (mouse) AHLPGTHSSGEAWPF S533
CCDC9 (rat) PTLAGTLKSEEEGSE K538
S530-p
GEAWPFEsV______
0 2
CCDC9 (human) GEAWPFEsV______ S530-p
CCDC9 (mouse) GEAWPFANA______ N542
CCDC9 (rat) AEITDFQRVRFCKVV R574